Qian Zhao

发表

Rapeseed Protein-Derived Antioxidant Peptide RAP Ameliorates Nonalcoholic Steatohepatitis and Related Metabolic Disorders in Mice.

Xianxing Jiang, Qian Zhao, Hongjiao Xu, 2018, Molecular pharmaceutics.

Suzuki Cross-Coupling Reaction with Genetically Encoded Fluorosulfates for Fluorogenic Protein Labeling.

Xianxing Jiang, Yani Zhou, Qian Zhao, 2020, Chemistry.

Site-specific labeling of an anti-MUC1 antibody: probing the effects of conjugation and linker chemistry on the internalization process

Xianxing Jiang, Qian Zhao, Hongjiao Xu, 2019, RSC advances.

AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis

Xianxing Jiang, Lili Jiang, Huihao Zhou, 2020, Nature Communications.

Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis by modulating mitochondrial function

Xianxing Jiang, Qian Zhao, Hongjiao Xu, 2022 .

Novel antimicrobial peptide CPF‐C1 analogs with superior stabilities and activities against multidrug‐resistant bacteria

Xianxing Jiang, Rui Wang, Qian Zhao, 2017, Chemical biology & drug design.

Synergistic activation of AMPK by AdipoR1/2 agonist and inhibitor of EDPs–EBP interaction recover NAFLD through enhancing mitochondrial function in mice

Xianxing Jiang, Qian Zhao, Hongjiao Xu, 2022, Acta pharmaceutica Sinica. B.

RAP-8 ameliorates liver fibrosis by modulating cell cycle and oxidative stress.

Xianxing Jiang, Qian Zhao, Hongjiao Xu, 2019, Life sciences.

The antimicrobial peptide YD attenuates inflammation via miR-155 targeting CASP12 during liver fibrosis

Xianxing Jiang, Qian Zhao, Hongjiao Xu, 2020, Acta pharmaceutica Sinica. B.

Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis

Xi Sun, Zhongdao Wu, Xianxing Jiang, 2021, Acta pharmaceutica Sinica. B.

A CDR-based approach to generate covalent inhibitory antibody for human rhinovirus protease.

Huayao Chen, Jingyuan Wu, Xianxing Jiang, 2021, Bioorganic & medicinal chemistry.

Discovery and Design of Novel Cyclic Peptides as Specific Inhibitors Targeting CCN2 and Disrupting CCN2/EGFR Interaction for Kidney Fibrosis Treatment.

Han Liu, Jianyi Li, Xianxing Jiang, 2023, Journal of medicinal chemistry.

Design and Discovery of Novel Cyclic Peptides as EDPs-EBP Interaction Inhibitors for the Treatment of Liver Fibrosis.

Xianxing Jiang, Qian Zhao, Nazi Song, 2023, Journal of medicinal chemistry.

Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis

Xianxing Jiang, Qian Zhao, Hongjiao Xu, 2023, Acta pharmaceutica Sinica. B.